


Amyotrophic lateral sclerosis carries a median survival of 2-5 years from symptom onset, with respiratory failure the cause of death in up to 95% of patients. The CDC National ALS Registry estimated approximately 33,000 people living with ALS in the United States in 2022, projected to rise more than 10% by 2030 as the population ages. Among Medicare beneficiaries, roughly 40% of ALS patients died within one year of their first diagnostic code or never saw a neurologist, with 25.5% dying within six months, evidence of substantial under-ascertainment in older adults and a reminder that early recognition and precise coding carry outsized clinical weight.
AAVBC's ALS Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity (G12.21 vs. G12.20) and HCC 190/RAF mapping, Gold Coast and revised El Escorial diagnostic criteria, ALSFRS-R and King's College staging, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAN-aligned multidisciplinary treatment across respiratory, nutritional, and cognitive domains. Grounded in AAN guidance and current CMS coding requirements, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early and document disease progression with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ALS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.


Amyotrophic lateral sclerosis carries a median survival of 2-5 years from symptom onset, with respiratory failure the cause of death in up to 95% of patients. The CDC National ALS Registry estimated approximately 33,000 people living with ALS in the United States in 2022, projected to rise more than 10% by 2030 as the population ages. Among Medicare beneficiaries, roughly 40% of ALS patients died within one year of their first diagnostic code or never saw a neurologist, with 25.5% dying within six months, evidence of substantial under-ascertainment in older adults and a reminder that early recognition and precise coding carry outsized clinical weight.
AAVBC's ALS Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering ICD-10 coding specificity (G12.21 vs. G12.20) and HCC 190/RAF mapping, Gold Coast and revised El Escorial diagnostic criteria, ALSFRS-R and King's College staging, geriatric risk factors and subtle early signs, MEAT documentation standards, and AAN-aligned multidisciplinary treatment across respiratory, nutritional, and cognitive domains. Grounded in AAN guidance and current CMS coding requirements, this guide supports consistent, individualized clinical decision-making, helping care teams recognize red-flag presentations early and document disease progression with the specificity risk adjustment requires, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of ALS — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.